{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-196457","form_type":"8-K","ticker":"GRTX","cik":"0001563577","company_name":"Galera Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.532374+00:00","generated_at":"2026-05-31T10:54:23.426260+00:00","sec_items":["7.01"],"event_type":"litigation","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Galera settles Phase 3 ROMAN trial CRO lawsuit for $975,000","bullets":["Settlement with Alira Health Clinical and IQVIA Biotech resolves breach-of-contract and negligence claims.","CROs paid $975,000 in exchange for mutual releases and termination of contracts with no further obligations.","Lawsuit stemmed from a 2021 error in statistical programming for the Phase 3 ROMAN trial of avasopasem.","Galera expects to file a Praecipe to end the litigation by August 8, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-196457","json":"https://secwatch.observer/filing/0001193125-24-196457.json","markdown":"https://secwatch.observer/filing/0001193125-24-196457.md","text":"https://secwatch.observer/filing/0001193125-24-196457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524196457/0001193125-24-196457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1563577/000119312524196457/d792052d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:54:23.426260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}